Ark says cancer therapy potent, cuts side-effects
|
Tweet
|
|
Britain’s Ark Therapeutics Plc said on Monday its cancer treatment had been found to be highly effective in stopping tumour development using only one tenth of the usual chemotherapy dose.
The biotechnology company said thanks to its DNA-based drug-targeting technology Scavidin treatments such as radiation or chemotherapy could be given in lower doses to reduce side-effects.
“These results indicate that Scavidin has the potential both to improve the therapeutic effect and to reduce the unpleasant side-effects of a wide variety of drugs,” Chief Executive Nigel Parker said in a statement.
The biotechnology has “enormous potential” across many disease areas, the group added.
Shares in Ark Therapeutics closed at 93-1/2 pence on Friday, valuing the group at about 119 million pounds ($207 million).
Revision date: July 5, 2011
Last revised: by Amalia K. Gagarina, M.S., R.D.
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
| Interactive Quiz: |



